Director (or Senior Director) Non-Clinical PK/PDBright Peak Therapeutics is looking for an experienced and highly motivated scientist to lead our PK/PD activities within our NCD team. The position allows you to have an immediate impact on the development of Bright Peak’s growing pipeline of novel multi-specific immunoconjugates by contributing expertise and scientific skills to both project teams and broader strategic discussions. As a small company, the role is both leadership and hands-on experimental design and execution, in close collaboration with our network of consultants and CRO partners.The ideal applicant has a strong background in biologics NCD, including work with complex multi-specific formats. Building on a profound knowledge of the subject matter, you will help lead our quest to develop novel multi-functional therapeutics. We look for a broad outlook and enthusiasm for exploring new therapeutic areas, but success in the development of immuno-oncology projects is essential.The position is based in Allschwil, on the outskirts of Basel, and although there is flexibility in working from home, we look for a predominantly on-site presence.ResponsibilitiesDesign and implement integrated non-clinical PK/PD strategies from research and discovery through early clinical development.Work within cross-functional teams to ensure alignment of non-clinical DMPK activities with overall program objectives.Design and execute PK/PD studies enabling first-in-human trials. Ensure studies are conducted in a timely, high-quality, and scientifically sound manner.Manage, analyse, review, summarise, interpret, report, and communicate results from PK/PD studies.Elaborate and implement PK/PD optimization strategies, including obtaining appropriate exposure in preclinical species for safety testing, minimizing potential safety liabilities, and supporting human PK and dose predictions.Oversee, author, and review non-clinical sections of regulatory documents and reports.Ensure compliance with regulatory requirements and represent the non-clinical development function in interactions with health authorities.Select, manage, and monitor external CROs and consultants.Stay current with the latest developments and approaches in the field.QualificationsPhD in Pharmaceutical or Life Sciences with 5–10 years of relevant experience in non-clinical development within the biotechnology or pharmaceutical industry.Proven track record of advancing biotherapeutic candidates from early research through non-clinical development, IND submission and beyond.Strong experience in the non-clinical development of therapeutic proteins, with broad expertise in PK/PD, pharmacology, and safety principles of biotherapeutics.Familiarity with GLP regulations, guidelines, and regulatory requirements for non-clinical development, along with experience in regulatory submissions and interactions.Relevant expertise in immuno-oncology. Additional expertise and experience in cardiometabolic diseases is a plus.Demonstrated ability to design, interpret, and report PK/PD studies.Track-record of working with CROs, academic partners, and external expert consultants.Personal SkillsHighly motivated with a can-do attitude and passion for working in a dynamic, fast-paced, and entrepreneurial environment with rapidly changing priorities and deadlines.Proven ability to build, maintain and influence effective working relationships with key internal and external stakeholders.Exceptional leadership, communication, and interpersonal skills.Good planning skills and strength in delivering outputs on agreed timelines.Able to work both independently as well as part of a team.About Bright Peak TherapeuticsBright Peak Therapeutics is a pioneering Basel and San Diego-based biotech using a blend of chemical synthesis, protein engineering and recombinant technology to create and develop immunotherapies for cancer and other therapeutic areas. We produce and chemically conjugate enhanced cytokine payloads to existing antibodies to generate “Bright Peak Immunoconjugates”. The company was spun out from the ETH Zürich in 2017 and is currently conducting Phase 1 clinical trials for a PD1-IL18 immunoconjugate (BPT567).In addition to salary compensation and equity, we offer a comfortable working environment, modern and well-equipped offices and labs, drinks and snacks, regular social events, free parking if needed and we aim for a supportive, enjoyable and inclusive work culture. Diversity and equality of opportunity is important to us, and we encourage applications from people of all social and cultural backgrounds. #J-18808-Ljbffr